Table of Contents

company-logo

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Daré Bioscience Dividend Announcement

• Daré Bioscience does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Daré Bioscience dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Daré Bioscience Dividend History

Daré Bioscience Dividend Yield

Daré Bioscience current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Daré Bioscience stock? Use our calculator to estimate your expected dividend yield:

Daré Bioscience Financial Ratios

P/E ratio-7.72
PEG ratio0.35
P/B ratio-18.74
ROE97.03%
Payout ratio0.00%
Current ratio1.14
Quick ratio1.14
Cash Ratio0.85

Daré Bioscience Dividend FAQ

Does Daré Bioscience stock pay dividends?
Daré Bioscience does not currently pay dividends to its shareholders.
Has Daré Bioscience ever paid a dividend?
No, Daré Bioscience has no a history of paying dividends to its shareholders. Daré Bioscience is not known for its dividend payments.
Why doesn't Daré Bioscience pay dividends?
There are several potential reasons why Daré Bioscience would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Daré Bioscience ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Daré Bioscience has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Daré Bioscience a dividend aristocrat?
Daré Bioscience is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Daré Bioscience a dividend king?
Daré Bioscience is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Daré Bioscience a dividend stock?
No, Daré Bioscience is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Daré Bioscience stocks?
To buy Daré Bioscience you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Daré Bioscience stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.